STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Terminated
- Recurrent Neuroblastoma
- Neuroblastoma
- Fenretinide/LXS Oral Powder
- +2 more
- Chicago, Illinois
- +3 more
2022-03-17
Mar 17, 2022C
Recruiting
- Treatment-naïve
- Peripheral T Cell Lymphoma
- Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
2021-07-26
Jul 26, 2021U
Terminated
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +10 more
- Cytarabine
- +3 more
- Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
2021-11-17
Nov 17, 2021F
Not yet recruiting
- PI3Kδ Inhibitor
- +3 more
- (no location specified)
2022-02-10
Feb 10, 2022N
Not yet recruiting
- Sarcoma, Ewing
- Rhabdomyosarcoma
- PEN-866
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022R
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
- Buffalo, New YorkRoswell Park Cancer Institute
2022-01-13
Jan 13, 2022A
Active, not recruiting
- Lymphoma, Non-Hodgkin
- +5 more
- Rituximab
- +2 more
- Providence, Rhode IslandRhode Island Hospital and The Miriam Hospital
2021-07-19
Jul 19, 2021E
Recruiting
- B Acute Lymphoblastic Leukemia
- +5 more
- Laboratory Biomarker Analysis
- +2 more
- New Haven, Connecticut
- +8 more
2021-03-04
Mar 4, 2021M
Completed
- Leukemia
- Rituximab
- +11 more
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2020-11-12
Nov 12, 2020B
Terminated
- Kaposiform Hemangioendothelioma (KHE)
- +2 more
- Vincristine
- Sirolimus
- Palo Alto, California
- +6 more
2021-05-20
May 20, 2021D
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- Tampa, Florida
- +2 more
2022-02-14
Feb 14, 2022C
Completed
- Intraocular Retinoblastoma
- liposomal vincristine sulfate
- +5 more
- Arcadia, California
- +10 more
2021-07-12
Jul 12, 2021U
Recruiting
- Diffuse Large B Cell Lymphoma
- R-CHOP
- R-CHOP + acalabrutinib
- Colchester, Essex, United Kingdom
- +2 more
2021-10-20
Oct 20, 2021H
Recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab
- +6 more
- Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2021-08-15
Aug 15, 2021M
Active, not recruiting
- Lymphoma
- pegfilgrastim
- +8 more
- Scottsdale, Arizona
- +2 more
2022-01-07
Jan 7, 2022U
Completed
- Kidney Cancer
- +5 more
- glutamic acid
- placebo
- Fort Myers, Florida
- +5 more
2021-07-22
Jul 22, 2021S
Active, not recruiting
- Retinoblastoma
- Retinal Neoplasm
- Enucleation
- +9 more
- Memphis, TennesseeSt. Jude Children's Research Hospital
2022-01-10
Jan 10, 2022U
Completed
- Lymphoma
- pegfilgrastim
- +5 more
- (no location specified)
2021-07-02
Jul 2, 2021U
Terminated
- Peripheral Neuropathy
- Candesartan
- Usual care
- Limoges, FranceCHU Limoges
2021-11-12
Nov 12, 2021S
Not yet recruiting
- Primary Extranodal Lymphoma
- DLBCL
- (no location specified)
2022-04-06
Apr 6, 2022M
Not yet recruiting
- Solid Tumor
- Atezolizumab
- +3 more
- Dallas, TexasThe University of Texas Southwestern Medical Center
2022-03-29
Mar 29, 2022N
Completed
- Neuroblastoma
- 131I-MIBG
- +3 more
- Los Angeles, California
- +13 more
2021-12-21
Dec 21, 2021C
Recruiting
- Chemotherapy-induced Peripheral Neuropathy
- No Intervention, Observational Study
- Washington, District of ColumbiaChildren's National Health System
2021-10-04
Oct 4, 2021H
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
- Rituximab
- +5 more
- Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2022-01-22
Jan 22, 2022T
Active, not recruiting
- Retinoblastoma
- filgrastim
- +6 more
- Vancouver, British Columbia, Canada
- +5 more
2021-10-22
Oct 22, 2021